A takeover symbolising the push to beef up Sanofi’s oncology pipeline is taken back to the drawing board.
The market’s reaction to positive clinical data has largely held up through the downturn, but failures have really, really hurt.
It is hard to see a combination of the two businesses as much beyond a defensive move in troubled times.
The demise of Nektar’s bempegaldesleukin has not stemmed the tidal wave of companies developing IL-2 and IL-15 therapies.
The big pharma becomes the latest to look at IL-2 to harness regulatory T cells, but plenty of others have the same idea.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
Kodiak, Biomarin and Argenx prepare for clinical catalysts.